Enanta Pharma (ENTA) Tops Q1 EPS by 23c

Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $1.36, $0.23 better than the analyst estimate of $1.13. Revenue for the quarter came in at $48.4 million versus the consensus estimate of $47.05 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Owlet (OWLT) Tops Q2 EPS by 9c
• Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c